国际儿科学杂志2021年3月第48卷第3期Int JPediatr,Mar2021,Vol.48,No.3•201・
医学杂志,2016,39(11)：814-816.DOI：10.3760/cma.j.issn.1009-9158.2016.11.004.
[16]叶青，尚世强•儿童过敏性疾病实验室检查的现状与进展[J].中
华检验医学杂志,2020,43(5)：515-519.DOI：10.3760/cma.j.
cnl14452-20191105-00643.
[17]Hamilton RG,Adkinson NF Jr.23.Clinical laboratory asssment of
IgE-dependent hypernsitivity[J].J Allergy Clin Immunol,2003, 111(2Suppl)：S687-701.DOI：10.1067/mai.2003.123.
[18]Glovsky MM.Measuring allergen-specific IgE:where have we been
and where are we going?[J].Methods Mol Biol,2007,378:205-219.DOI：10.1007/978-1-59745-323-3J5.
[19]王瑞琦，张宏誉.CAP系统检测过敏原特异性IgE抗体的方法学
评价[J].临床检验杂志,2007,25(2)；109-110.DOI；10.3969/j.
issn.1001-764X.2007.02.011.
[20]Hamid OA,Elfedawy S,Mohamed SK,et al.Immunoblotting tech
nique:a new accurate in vitro test for detection of allergen-specific IgE in allergic rhinitis[J].Eur Arch Otorhinolaryngol,2009,266
(10)J569-1573.DOI：10.1007/s00405-009-0972-1.
[21]Jeon H,Jung JH,Kim Y,et al.Allergen microarrays for In vitro diag
nostics of allergies:comparison with ImmunoCAP and advansure [J].Ann Lab Med,2018,38(4)：338-347.DOI：10.3343/alm.
2018.38.4.338.
[22]Wongpiyabovom J,Suratannon N,Boonmee S,et al.Comparison of
specific IgE detection by immunoblotting and fluorescence enzyme assay with in vivo skin prick test[J].Asian Pac J Allergy Immunol, 2018,36(3)：159-165.DOI：10.12932/AP-270217-0035.[23]Goodman RE,Chapman MD,Slater JE.The allergen:sources,ex
tracts,and molecules for diagnosis of allergic dia[J].J Allergy Clin Immunol Pract,2020,8(8)：2506-2514.DOI：10.1016/j.jaip.
2020.06.043.
[24]Shoormasti RS,Fazlollahi MR,Kazemnejad A,et al.Accuracy of im
munoblotting assay for detection of specific IgE compared with ImmunoCAP in allergic patients[J].Electron Physician,2018,10(2): 63274332.DOI：10.19082/6327.
[25]王学艳，陈艳蕾，兰天飞•过敏原检测的定量发展趋势[J].中华检
验医学杂志,2018,41(12):971-974.DOI：10.3760/cma.j.issn.
1009-9158.2018.12.015.
[26]Graham F,Begin P,Paradis L,et al.Comparison of ImmunoCAP and
immulite rum specific IgE assays for the asssment of egg allergy [J].Allergy Asthma Clin Immunol,2016,12:29.DOI：10.1186/ S13223-016-0134-0.
[27]Hamilton RG,Hemmer W,Nopp A,et al.Advances in IgE testing for
diagnosis of allergic dia[J].J Allergy Clin Immunol Pract,2020, 8(8)：2495-2504.DOI：10.1016/j.jaip.2020.07.021.
[28]Chen H,Li J,Cheng L,et al.China connsus document on allergy
diagnostics[J].Allergy Asthma Immunol Res,2021,13(2):177-205.DOI：10.4168/aair.2021.13.2.177.
(收稿日期:2020-12-08)
(本文编辑：侯萍)•Acta Paediatrica科研论文快递•
............................................................................................................................................................in,,
微创注入肺表面活性物质后极早产儿的发育结局改善：LISA 后的发育结局
目的评估胎龄23-26周的早产儿应用微创注入肺表面活性物质(LISA)后在矫正年龄24个月时的神经认知结局。
方法回顾性分析德国13个三级新生儿重症监护病房LISA 试验的存活患儿，评估患儿的神经发育结局、
听觉、视觉、生长发育状况、再住院天数及潜在混杂因素如母亲抑郁、母乳喂养率和社会经济因素等。
结果182例存活患儿中有156例纳入研究，其中78例LISA,78例气管插管注入肺表面活性物质。22%的LISA婴儿和42%的插管婴儿精神运动发育指数(PDI)<70(P=0.012)。在胎龄25~26周的较成熟早产儿中，两组智力发育指数(MDI)存在显著差异,4%的LISA婴儿和21%的插管婴儿MDI<70(P=0.008)o
结论矫正年龄24个月时,LISA婴儿的PDK70比例较低，MDI得分与插管婴儿相似，胎龄25-26周的早产儿接受LISA 治疗后的严重致残率降低。LISA技术安全、更优。
石永言译自Acta Paediatrica2021,110,818-825.
